Worth reading
22Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Definitive
How definitive the wording is.Who is moving to which position
Resolved 10 April 2026 (extraordinary general meeting of shareholders of スペラネクサス株式会社)Incoming appointee
1 itemScheduled Appointment DateEffective 10 April 2026
Naruse Hirotoshi (成瀬 寛俊)
Previous positionManaging Executive Officer, Pharmaceutical Business; concurrently Head of the FC and Pharmaceutical Business Structural Reform Office; concurrently Director of スペラファーマ株式会社; concurrently Director of 岩城製薬佐倉工場株式会社
New positionManaging Executive Officer, Pharmaceutical Business; concurrently Head of the FC and Pharmaceutical Business Structural Reform Office; concurrently Director of スペラファーマ株式会社; concurrently Director of 岩城製薬佐倉工場株式会社; concurrently Director of スペラネクサス株式会社
Shareholders’ meeting approvalNot required (the election was approved at the extraordinary general meeting of shareholders held on 10 April 2026)
| Item | Details |
|---|---|
| Resolution date | 10 April 2026 (extraordinary general meeting of shareholders of スペラネクサス株式会社) |
| Scheduled Appointment Date | Effective 10 April 2026 |
| Name of appointee | Naruse Hirotoshi (成瀬 寛俊) |
| Appointee's new position | Managing Executive Officer, Pharmaceutical Business; concurrently Head of the FC and Pharmaceutical Business Structural Reform Office; concurrently Director of スペラファーマ株式会社; concurrently Director of 岩城製薬佐倉工場株式会社; concurrently Director of スペラネクサス株式会社 |
| Appointee's previous position | Managing Executive Officer, Pharmaceutical Business; concurrently Head of the FC and Pharmaceutical Business Structural Reform Office; concurrently Director of スペラファーマ株式会社; concurrently Director of 岩城製薬佐倉工場株式会社 |
| Subject to Approval by the General Meeting of Shareholders | Not required (the election was approved at the extraordinary general meeting of shareholders held on 10 April 2026) |
Items this document does not state (15)
Date of departureAppointee's date of birthYear the appointee joined the CompanyNumber of shares held by the appointeeName of departing officerFormer position of departing officerNew position of departing officerReason for departureWhether the incumbent will remain in officeReason for changeReasons for appointmentNumber of directors after the changeFiling as an independent officerDetails of organizational changesChange in Corporate Governance Structure
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The Company states that it is announcing the personnel change because the election of the director was approved at an extraordinary general meeting of shareholders of スペラネクサス株式会社.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.